Display options
Cite
Furuse M, Nonoguchi N, Kuroiwa T, et al. A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neurooncol Pract. 2016;3(4):272-280doi: 10.1093/nop/npv064.
Furuse, M., Nonoguchi, N., Kuroiwa, T., Miyamoto, S., Arakawa, Y., Shinoda, J., Miwa, K., Iuchi, T., Tsuboi, K., Houkin, K., Terasaka, S., Tabei, Y., Nakamura, H., Nagane, M., Sugiyama, K., Terasaki, M., Abe, T., Narita, Y., Saito, N., Mukasa, A., Ogasawara, K., Beppu, T., Kumabe, T., Nariai, T., Tsuyuguchi, N., Nakatani, E., Kurisu, S., Nakagawa, Y., & Miyatake, S. I. (2016). A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-oncology practice, 3(4), 272-280. https://doi.org/10.1093/nop/npv064
Furuse, Motomasa, et al. "A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis." Neuro-oncology practice vol. 3,4 (2016): 272-280. doi: https://doi.org/10.1093/nop/npv064
Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI. A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neurooncol Pract. 2016 Dec;3(4):272-280. doi: 10.1093/nop/npv064. Epub 2016 Jan 07. PMID: 27833757; PMCID: PMC5099992.
Copy Download .nbib Format: NLM
Share it on

Neurooncol Pract. 2016 Dec;3(4):272-280. doi: 10.1093/nop/npv064. Epub 2016 Jan 07.

A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis.

Neuro-oncology practice

Motomasa Furuse, Naosuke Nonoguchi, Toshihiko Kuroiwa, Susumu Miyamoto, Yoshiki Arakawa, Jun Shinoda, Kazuhiro Miwa, Toshihiko Iuchi, Koji Tsuboi, Kiyohiro Houkin, Shunsuke Terasaka, Yusuke Tabei, Hideo Nakamura, Motoo Nagane, Kazuhiko Sugiyama, Mizuhiko Terasaki, Tatsuya Abe, Yoshitaka Narita, Nobuhito Saito, Akitake Mukasa, Kuniaki Ogasawara, Takaaki Beppu, Toshihiro Kumabe, Tadashi Nariai, Naohiro Tsuyuguchi, Eiji Nakatani, Shoko Kurisu, Yoko Nakagawa, Shin-Ichi Miyatake

Affiliations

  1. Department of Neurosurgery , Osaka Medical College , Takatsuki, Osaka , Japan (M.F., N.N., T.K., S.-I.M.); Department of Neurosurgery , Kyoto University Graduate School of Medicine , Kyoto , Japan (S.M., Y.A.); Department of Neurosurgery, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction , Kizawa Memorial Hospital , Minokamo , Japan (J.S., K.M.); Division of Neurological Surgery , Chiba Cancer Center , Chiba , Japan (T.I.); Proton Medical Research Center , University of Tsukuba , Tsukuba , Japan (K.T.); Department of Neurosurgery , Hokkaido University Graduate School of Medicine , Sapporo , Japan (K.H., S.T.); Department of Neurosurgery , Japanese Red Cross Medical Center , Tokyo , Japan (Y.T.); Department of Neurosurgery , Kumamoto University Graduate School of Medical Science , Kumamoto , Japan (H.N.); Department of Neurosurgery , Kyorin University Faculty of Medicine , Mitaka , Japan (M.N.); Department of Clinical Oncology and Neuro-oncology Program , Hiroshima University Hospital , Hiroshima , Japan (K.S.); Department of Neurosurgery , Kurume University School of Medicine , Kurume , Japan (M.T.); Department of Neurosurgery , Oita University Faculty of Medicine , Oita , Japan (T.A.); Department of Neurosurgery and Neuro-Oncology , National Cancer Center Hospital , Tokyo , Japan (Y.N.); Department of Neurosurgery , The University of Tokyo , Tokyo , Japan (N.S., A.M.); Department of Neurosurgery , Iwate Medical University , Morioka , Japan (K.O.); Department of Neurosurgery, Division of Hyperbaric Medicine , Iwate Medical University , Morioka , Japan (T.B.); Department of Neurosurgery , Kitasato University School of Medicine , Sagamihara , Japan (T.Kum); Department of Neurosurgery , Tokyo Medical and Dental University , Tokyo , Japan (T.N.); Department of Neurosurgery , Osaka City University Graduate School of Medicine , Osaka , Japan (N.T.); Translational Research Informatics Center , Foundation for Biomedical Research and Innovation , Kobe , Japan (E.N., S.K., Y.N.).

PMID: 27833757 PMCID: PMC5099992 DOI: 10.1093/nop/npv064

Abstract

BACKGROUND: Brain radiation necrosis (BRN) can be a complication of radiotherapy for primary and secondary brain tumors, as well as head and neck tumors. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain, bevacizumab, a humanized antibody that inhibits VEGF, would be expected to reduce perilesional edema that often accompanies BRN.

METHODS: Patients with surgically untreatable, symptomatic BRN refractory to conventional medical treatments (eg, corticosteroid, anticoagulants, or hyperbaric oxygen therapy) were enrolled. We judged that a major cause of perilesional edema with a lesion-to-normal brain ratio ≤1.8 on

RESULTS: Of the 41 patients enrolled, 38 were fully eligible for the response assessment. The primary endpoint was achieved in 30 of the 38 (78.9%) patients at 3.0 months (median) after enrollment. Sixteen patients (42.1%) experienced improvement of their Karnofsy Performance Score. Corticosteroid use could be reduced in 29 patients (76.3%). Adverse events at grade ≥3 occurred in 10 patients (24.4%).

CONCLUSIONS: Bevacizumab treatment offers certain clinical benefits for patients with surgically untreatable, symptomatic BRN. The determination of BRN using amino-acid PET, not biopsy, is adequate and less invasive for determining eligibility to receive bevacizumab.

Keywords: Bevacizumab; brain radiation necrosis; positron emission tomography; vascular endothelial growth factor

References

  1. Neurology. 1994 Nov;44(11):2020-7 - PubMed
  2. J Neurooncol. 2008 Sep;89(2):239-46 - PubMed
  3. Cancer. 1984 Nov 1;54(9):1966-72 - PubMed
  4. J Neurooncol. 2011 May;102(3):471-5 - PubMed
  5. Brain. 2002 Nov;125(Pt 11):2549-57 - PubMed
  6. Neurol Med Chir (Tokyo). 2009 Sep;49(9):394-401 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 - PubMed
  8. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5888-95 - PubMed
  9. N Engl J Med. 2014 Feb 20;370(8):709-22 - PubMed
  10. J Neurooncol. 2013 Nov;115(2):217-23 - PubMed
  11. J Nucl Med. 2008 May;49(5):694-9 - PubMed
  12. J Neurooncol. 2011 Nov;105(2):423-31 - PubMed
  13. J Neurooncol. 2015 Mar;122(1):145-50 - PubMed
  14. Radiat Oncol. 2014 Jan 06;9:6 - PubMed
  15. J Neurooncol. 2014 Aug;119(1):101-9 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95 - PubMed
  17. Ann Nucl Med. 2011 Apr;25(3):213-20 - PubMed
  18. J Clin Oncol. 2009 Oct 1;27(28):4733-40 - PubMed
  19. Neuro Oncol. 2009 Aug;11(4):430-6 - PubMed
  20. Surg Neurol. 1978 Nov;10(5):281-90 - PubMed
  21. Neuro Oncol. 2013 Sep;15(9):1257-63 - PubMed
  22. Clin Neurol Neurosurg. 2010 Nov;112(9):758-65 - PubMed
  23. J Neurol Neurosurg Psychiatry. 1987 Nov;50(11):1407-14 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 - PubMed
  25. Neuro Oncol. 2014 Sep;16(9):1255-62 - PubMed
  26. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51 - PubMed
  27. Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):685-90 - PubMed
  28. Neuro Oncol. 2013 Jun;15(6):650-5 - PubMed
  29. Neuro Oncol. 2013 Feb;15(2):242-50 - PubMed
  30. Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S348-50 - PubMed
  31. J Neurooncol. 2008 Dec;90(3):357-62 - PubMed
  32. J Neurooncol. 2009 Aug;94(1):63-8 - PubMed
  33. J Neurosurg. 2003 May;98 (5):1056-64 - PubMed
  34. J Neurosurg. 1984 Mar;60(3):589-94 - PubMed
  35. Eur J Med Res. 2012 Aug 23;17:25 - PubMed
  36. Ann Nucl Med. 2004 Jun;18(4):291-6 - PubMed
  37. Jpn J Clin Oncol. 2013 Mar;43(3):337-41 - PubMed

Publication Types